TELA BIO ($NASDAQ:TELA) reported their financial results for the second quarter of Fiscal Year 2023 on June 30, 2023. Total revenue for the quarter increased by 39.2% to USD 14.5 million compared to the same quarter of the prior year, while net income experienced a slight decrease from -12.7 million to -10.8 million.
On Wednesday, TELA BIO reported positive earnings for the second quarter of fiscal year 2023. The company’s stock opened at $9.2 and closed at $9.1, a 1.5% decrease from its previous closing price of $9.2. Despite the slight dip in stock price, TELA BIO’s strong quarterly performance was still a positive indicator for shareholders. The company’s revenue was driven mainly by the introduction of its new BIONIC line of medical devices, which has been well received by both consumers and doctors alike.
The positive earnings report reflects TELA BIO’s commitment to innovation and customer satisfaction. Moreover, the company expects to continue to build on its success and deliver even better results in the next quarter. As the company continues to expand its product line and maintain strong relationships with its customers, investors can expect TELA BIO to remain a strong player in the medical device industry for years to come. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Tela Bio. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tela Bio. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tela Bio. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Tela Bio are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Tela Bio Stock Intrinsic Value
GoodWhale recently conducted an analysis of TELA BIO‘s financials, and determined its intrinsic value to be around $13.4. This was calculated using our proprietary Valuation Line tool, which utilizes a variety of metrics to determine a company’s true worth. By our assessment, the current market price of TELA BIO’s stock, at $9.1, is undervalued by 32.2%. This means that now might be a good time to invest in TELA BIO, as the stock is being sold at a price below its estimated true value. With this in mind, investors should take advantage of the current price discrepancy and consider investing in TELA BIO’s stock. More…
Risk Rating Analysis
Star Chart Analysis
The company’s products are used in a variety of procedures, including breast reconstruction, hernia repair, and abdominal wall reconstruction. TELA Bio‘s competitors include TransMedics Group, InMode Ltd, and Osprey Medical Inc.
– TransMedics Group Inc ($NASDAQ:TMDX)
TransMedics Group Inc is a medical technology company that develops, manufactures and sells organ transplantation products. The company’s products are designed to improve the quality of organs for transplantation and to increase the number of organs available for transplantation. TransMedics Group Inc has a market cap of 1.84B as of 2022, a Return on Equity of -20.11%. The company’s products are used by transplant centers around the world, and its products are sold in over 50 countries. TransMedics Group Inc is headquartered in Andover, Massachusetts.
InMode Ltd. is a technology company that provides minimally invasive aesthetic solutions. The company offers various solutions for skin tightening, body contouring, fat reduction, and facial rejuvenation. InMode Ltd. has a market cap of 3.06B as of 2022 and a Return on Equity of 28.88%. The company’s products are available in over 60 countries and are FDA-cleared, CE-marked, and TGA-registered.
TELA BIO, a healthcare technology company, reported their earnings for the second quarter of FY2023 on June 30, 2023. Total revenue increased significantly by 39.2% year-over-year to 14.5 million USD.
However, net income decreased slightly from -12.7 million to -10.8 million dollars. Investors should consider these results when analyzing the potential of investing in TELA BIO. With revenue growth continuing despite decreased net income, the company could be a strong choice for long-term investment. It is important to keep in mind that this company is still relatively new and that more time and data is needed before determining whether investing in TELA BIO is worthwhile.